Oak Harvest Investment Services Purchases 77,386 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Oak Harvest Investment Services grew its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 154.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,386 shares of the company’s stock after purchasing an additional 77,386 shares during the quarter. Oak Harvest Investment Services’ holdings in Teva Pharmaceutical Industries were worth $3,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 10.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,495 shares of the company’s stock worth $265,000 after purchasing an additional 788 shares during the period. PDS Planning Inc bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $236,000. United Advisor Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 9.3% in the fourth quarter. United Advisor Group LLC now owns 17,600 shares of the company’s stock worth $549,000 after purchasing an additional 1,500 shares during the period. CWM LLC boosted its position in shares of Teva Pharmaceutical Industries by 39.2% in the fourth quarter. CWM LLC now owns 7,462 shares of the company’s stock worth $233,000 after purchasing an additional 2,101 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 31.4% in the fourth quarter. Farther Finance Advisors LLC now owns 9,684 shares of the company’s stock worth $302,000 after purchasing an additional 2,313 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Richard Daniell sold 17,295 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 62,102 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the completion of the sale, the insider directly owned 224,940 shares in the company, valued at approximately $6,779,691.60. This represents a 21.64% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Barclays upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.78.

Teva Pharmaceutical Industries Stock Up 3.8%

Shares of NYSE TEVA opened at $32.45 on Friday. The firm’s 50-day moving average price is $31.52 and its 200-day moving average price is $28.57. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $37.31 billion, a price-to-earnings ratio of 27.04, a P/E/G ratio of 2.73 and a beta of 0.76. Teva Pharmaceutical Industries Ltd. has a 12-month low of $13.04 and a 12-month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.